Immunotherapy in Gynecologic Cancers: Are We There Yet?

被引:46
作者
Pakish, Janelle B. [1 ,2 ]
Jazaeri, Amir A. [3 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Unit 1362, 1155 Herman Pressler,CPB6-3258, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Reprod Med, 1155 Herman Pressler,CPB6-3258, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Unit 1362, 1155 Herman Pressler,CPB6-3558, Houston, TX 77030 USA
关键词
Immunotherapy; Checkpoint inhibitor; Cervical cancer; Ovarian cancer; Endometrial cancer; PD1; PD-L1; EPITHELIAL OVARIAN-CANCER; ANTI-PD-1; ANTIBODY; ENDOMETRIAL CANCER; ANTITUMOR-ACTIVITY; ADOPTIVE TRANSFER; THERAPY; SAFETY; TRIAL; AUTOIMMUNITY; VACCINATION;
D O I
10.1007/s11864-017-0504-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immune-targeted therapies have demonstrated durable responses in many tumor types with limited treatment options and poor overall prognosis. This has led to enthusiasm for expanding such therapies to other tumor types including gynecologic malignancies. The use of immunotherapy in gynecologic malignancies is in the early stages and is an active area of ongoing clinical research. Both cancer vaccines and immune checkpoint inhibitor therapy continue to be extensively studied in gynecologic malignancies. Immune checkpoint inhibitors, in particular, hold promising potential in specific subsets of endometrial cancer that express microsatellite instability. The key to successful treatment with immunotherapy involves identification of the subgroup of patients that will derive benefit. The number of ongoing trials in cervical, ovarian, and endometrial cancer will help to recognize these patients and make treatment more directed. Additionally, a number of studies are combining immunotherapy with standard treatment options and will help to determine combinations that will enhance responses to standard therapy. Overall, there is much enthusiasm for immunotherapy approaches in gynecologic malignancies. However, the emerging data shows that with the exception of microsatellite unstable tumors, the use of single-agent immune checkpoint inhibitors is associated with response rates of 10-15%. More effective and likely combinatorial approaches are needed and will be informed by the findings of ongoing trials.
引用
收藏
页数:13
相关论文
共 42 条
  • [1] Signatures of mutational processes in human cancer
    Alexandrov, Ludmil B.
    Nik-Zainal, Serena
    Wedge, David C.
    Aparicio, Samuel A. J. R.
    Behjati, Sam
    Biankin, Andrew V.
    Bignell, Graham R.
    Bolli, Niccolo
    Borg, Ake
    Borresen-Dale, Anne-Lise
    Boyault, Sandrine
    Burkhardt, Birgit
    Butler, Adam P.
    Caldas, Carlos
    Davies, Helen R.
    Desmedt, Christine
    Eils, Roland
    Eyfjord, Jorunn Erla
    Foekens, John A.
    Greaves, Mel
    Hosoda, Fumie
    Hutter, Barbara
    Ilicic, Tomislav
    Imbeaud, Sandrine
    Imielinsk, Marcin
    Jaeger, Natalie
    Jones, David T. W.
    Jones, David
    Knappskog, Stian
    Kool, Marcel
    Lakhani, Sunil R.
    Lopez-Otin, Carlos
    Martin, Sancha
    Munshi, Nikhil C.
    Nakamura, Hiromi
    Northcott, Paul A.
    Pajic, Marina
    Papaemmanuil, Elli
    Paradiso, Angelo
    Pearson, John V.
    Puente, Xose S.
    Raine, Keiran
    Ramakrishna, Manasa
    Richardson, Andrea L.
    Richter, Julia
    Rosenstiel, Philip
    Schlesner, Matthias
    Schumacher, Ton N.
    Span, Paul N.
    Teague, Jon W.
    [J]. NATURE, 2013, 500 (7463) : 415 - +
  • [2] [Anonymous], J CLIN ONCOL S
  • [3] [Anonymous], 2015, J Clin Oncol
  • [4] Aoki Y, CANC RES
  • [5] Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial
    Baek, Soyoung
    Kim, Yong-Man
    Kim, Sung-Bae
    Kim, Choung-Soo
    Kwon, Seog-Woon
    Kim, YongMan
    Kim, HyunSoo
    Lee, Hyunah
    [J]. CELLULAR & MOLECULAR IMMUNOLOGY, 2015, 12 (01) : 87 - 95
  • [6] Basu P, J CLIN ONCOL
  • [7] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
    Brahmer, Julie R.
    Tykodi, Scott S.
    Chow, Laura Q. M.
    Hwu, Wen-Jen
    Topalian, Suzanne L.
    Hwu, Patrick
    Drake, Charles G.
    Camacho, Luis H.
    Kauh, John
    Odunsi, Kunle
    Pitot, Henry C.
    Hamid, Omid
    Bhatia, Shailender
    Martins, Renato
    Eaton, Keith
    Chen, Shuming
    Salay, Theresa M.
    Alaparthy, Suresh
    Grosso, Joseph F.
    Korman, Alan J.
    Parker, Susan M.
    Agrawal, Shruti
    Goldberg, Stacie M.
    Pardoll, Drew M.
    Gupta, Ashok
    Wigginton, Jon M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) : 2455 - 2465
  • [8] Whole tumor antigen vaccines
    Chiang, Cheryl Lai-Lai
    Benencia, Fabian
    Coukos, George
    [J]. SEMINARS IN IMMUNOLOGY, 2010, 22 (03) : 132 - 143
  • [9] Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission
    Chu, Christina S.
    Boyer, Jean
    Schullery, Daniel S.
    Gimotty, Phyllis A.
    Gamerman, Victoria
    Bender, James
    Levine, Bruce L.
    Coukos, George
    Rubin, Stephen C.
    Morgan, Mark A.
    Vonderheide, Robert H.
    June, Carl H.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2012, 61 (05) : 629 - 641
  • [10] Dellinger TH, 2009, EXPERT REV ANTICANC, V9, P905, DOI [10.1586/era.09.54, 10.1586/ERA.09.54]